Current Management of Patients with Severe Acute Peripartum Cardiomyopathy: Practical Guidance from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Johann Bauersachs; Mattia Arrigo; Denise Hilfiker‐Kleiner; Christian Veltmann; Andrew J.S. Coats; María G. Crespo‐Leiro; Rudolf A. de Boer; Peter van der Meer; Christoph Maack; Frédéric Mouquet; Mark C. Petrie; Massimo Piepoli; Vera Regitz‐Zagrosek; Maria Schaufelberger; Petar Seferović; Luigi Tavazzi; Frank Ruschitzka; Alexandre Mebazaa; Karen Sliwa

doi:10.1002/ejhf.586

Key Points

To establish evidence-informed clinical guidance for diagnosing, stabilizing, and managing severe acute peripartum cardiomyopathy across the acute care continuum.
Synthesized existing pathophysiological data, clinical trials, and multicenter registry findings via the Heart Failure Association Study Group on Peripartum Cardiomyopathy.
Formulated interdisciplinary diagnostic algorithms and management protocols covering inotropic therapy, mechanical circulatory support, and obstetric delivery planning.
Recommends intensive cardiac care admission and early hemodynamic stabilization utilizing levosimendan over standard catecholamines to avoid metabolic stress, paired with adjunctive bromocriptine and anticoagulation.
Advises prioritizing temporary mechanical circulatory support (such as Impella or veno-arterial ECMO) as bridge-to-recovery rather than immediate bridge-to-transplantation due to high left ventricular recovery potential.
Highlights wearable cardioverter-defibrillators to safeguard against lethal ventricular arrhythmias during the first six months post-diagnosis prior to considering permanent implantable devices.

Structured PICO

P

Population

Patients with severe acute peripartum cardiomyopathy (PPCM) presenting with acute heart failure.

I

Intervention

Guideline-based management including optimization of preload, oxygenation, inotropes/vasopressors (preferring levosimendan over dobutamine/adrenaline), urgent delivery if pre-partum, and adjunctive bromocriptine with anticoagulation.

This HFA/ESC practical guidance provides a comprehensive algorithm for managing severe acute peripartum cardiomyopathy, addressing the unique pathophysiological and clinical challenges of these patients.

Limitations

Scarce evidence-based data from randomized clinical trials

Implication

Guides inotrope and adjunctive therapy choices in severe acute PPCM now; extends ESC recommendations with a dedicated practical algorithm.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bauersachs et al. (2016) studied this question.

synapsesocial.com/papers/69dbbf1550e1971baba3c659 https://doi.org/10.1002/ejhf.586

View Full Paper

Ask AI

Bookmark

Share

Current Management of Patients with Severe Acute Peripartum Cardiomyopathy: Practical Guidance from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Current Management of Patients with Severe Acute Peripartum Cardiomyopathy: Practical Guidance from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading